Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2024

This “Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Brutons Tyrosine Kinase (BTK) Inhibitors Understanding

Brutons Tyrosine Kinase (BTK) Inhibitors: Overview

Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase which plays a central role in the signal transduction of the B cell antigen receptor (BCR) and other cell surface receptors, both in normal and malignant B lymphocytes. BCR signaling is activated in secondary lymphatic organs and drives the proliferation of malignant B cells, including chronic lymphocytic leukemia (CLL) cells. During the last ten years, BTK inhibitors (BTKi) are increasingly replacing chemotherapy-based regimen, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). BTKi are particularly active in patients with CLL and MCL, but also received approval for Waldenström’s macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease. Long-term use of BTKi, however, is expensive and can be complicated by the emergence of long-term toxicities and/or resistance. Second generation kinase inhibitors may have an improved side-effect profile that may facilitate long-term use, while combination therapy approaches induce deeper remissions which opens the door to limited-duration therapy.

Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Brutons Tyrosine Kinase (BTK) Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brutons Tyrosine Kinase (BTK) Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Brutons Tyrosine Kinase (BTK) Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Brutons Tyrosine Kinase (BTK) Inhibitors.

Brutons Tyrosine Kinase (BTK) Inhibitors Emerging Drugs Chapters

This segment of the Brutons Tyrosine Kinase (BTK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Brutons Tyrosine Kinase (BTK) Inhibitors Emerging Drugs

Zanubrutinib: Bei GeneZanubrutinib (BGB-3111), a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. It is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström’s macroglobulinemia. In May 2021, BeiGene announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (s NDA) for BRUKINSA (zanubrutinib) for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy and grantedpriorityreview.

Rilzabrutinib: Principia Biopharma Rilzabrutinib (formerly known as PRN1008) is a BTK inhibitor, oral, first in class, wholly owned by Principia Biopharma is currently being evaluated in three different disease indications. It is currently in Phase III for Pemphigus, Immune Thrombocytopenia (ITP) and Phase II for autoimmune diseases like IgG4-Related Disease. Orphan drug designation is received from the United States Food and Drug Administration for rilzabrutinib for the treatment of pemphigus vulgaris and from the European Commission for the treatment of pemphigus (pemphigus vulgaris and pemphigusfoliaceus).

Brutons Tyrosine Kinase (BTK) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Brutons Tyrosine Kinase (BTK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Brutons Tyrosine Kinase (BTK) Inhibitors

There are approx. 30+ key companies which are developing the therapies for Brutons Tyrosine Kinase (BTK) Inhibitors. The companies which have their Brutons Tyrosine Kinase (BTK) Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, BeiGene.

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Brutons Tyrosine Kinase (BTK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Brutons Tyrosine Kinase (BTK) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brutons Tyrosine Kinase (BTK) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brutons Tyrosine Kinase (BTK) Inhibitors drugs.

Brutons Tyrosine Kinase (BTK) Inhibitors Report Insights

• Brutons Tyrosine Kinase (BTK) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Brutons Tyrosine Kinase (BTK) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Brutons Tyrosine Kinase (BTK) Inhibitors drugs?
• How many Brutons Tyrosine Kinase (BTK) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brutons Tyrosine Kinase (BTK) Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brutons Tyrosine Kinase (BTK) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Brutons Tyrosine Kinase (BTK) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Inno CarePharma
• BeiGene
• Principia Biopharma
• Carna Biosciences
• Loxo Oncology
• Aptose Biosciences
• Biogen

Key Products

• Orelabrutinib
• Zanubrutinib
• PRN473
• Rilzabrutinib
• AS-0871
• AS-1763
• Pirtobrutinib
• CG-806
• BIIB091

This product will be delivered within 1-3 business days.